Transcode Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Transcode Therapeutics
RNAZ Stock  USD 12.34  2.47  25.03%   
Transcode Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Transcode Therapeutics' valuation are provided below:
Market Capitalization
11.3 M
Earnings Share
(236.52)
We have found one hundred twenty available fundamental trend indicators for Transcode Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Transcode Therapeutics current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 25.7 M in 2026. Enterprise Value is likely to drop to about 19.4 M in 2026
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 315.4 K, Interest Expense of 29.3 K or Selling General Administrative of 6.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Transcode Stock
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Transcode Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7 M8.4 M3.6 M
Slightly volatile
Short and Long Term Debt Total32.7 K34.5 K512.9 K
Pretty Stable
Other Current Liabilities172 K181.1 K681.8 K
Slightly volatile
Total Current Liabilities2.2 M3.2 M1.2 M
Slightly volatile
Other Liabilities2.4 M2.3 M959.7 K
Slightly volatile
Cash5.6 M6.7 M2.9 M
Slightly volatile
Cash And Short Term Investments5.6 M6.7 M2.9 M
Slightly volatile
Common Stock Shares Outstanding430 K409.5 K73.5 K
Slightly volatile
Liabilities And Stockholders Equity7 M8.4 M3.6 M
Slightly volatile
Non Current Liabilities Total7.9 M7.5 M2.2 M
Slightly volatile
Other Current Assets1.3 M1.5 M589.1 K
Slightly volatile
Other Stockholder Equity73.9 M70.4 M18.6 M
Slightly volatile
Total Liabilities11.2 M10.7 M3.2 M
Slightly volatile
Total Current Assets6.7 M8.2 M3.5 M
Slightly volatile
Short Term Debt32.7 K34.5 K429.4 K
Pretty Stable
Common Stock88.0792.7573
Slightly volatile
Accounts Payable2.1 M3 M985.4 K
Slightly volatile
Non Current Assets Total287.2 K231.3 K129.2 K
Slightly volatile
Long Term Debt1.7 M2.4 M1.4 M
Slightly volatile
Common Stock Total Equity371418456
Slightly volatile
Capital Stock88.0792.7473
Pretty Stable
Net Working Capital5.3 M5 M2.4 M
Slightly volatile
Short Term Investments11.4 K10.8 K3 K
Slightly volatile
Deferred Long Term Liabilities179.3 K201.7 K220.2 K
Slightly volatile
Current Deferred Revenue22.1 K22.9 K28.9 K
Slightly volatile
Property Plant And Equipment Gross512 K460.1 K326.9 K
Slightly volatile
Property Plant Equipment165 K185.6 K202.6 K
Slightly volatile
Net Receivables288.2 K324.2 K353.9 K
Slightly volatile
Inventory443.5 K498.9 K544.5 K
Slightly volatile

Transcode Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization315.4 K481.4 K389.9 K
Very volatile
Selling General Administrative6.5 M6.8 M422.9 M
Pretty Stable
Other Operating Expenses9.7 M18 M5.4 M
Slightly volatile
Research Development5.6 M11.1 M3.1 M
Slightly volatile
Total Operating Expenses9.5 M17.4 M5.3 M
Slightly volatile
Interest Income7477872.3 K
Slightly volatile
Cost Of Revenue328 K615.1 K153.1 K
Slightly volatile
Selling And Marketing Expenses5.7 B6.4 B7 B
Slightly volatile

Transcode Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.1 M2 M445.5 K
Slightly volatile
Begin Period Cash Flow4.7 M3.2 M2.2 M
Slightly volatile
Depreciation645.8 K615.1 K171.8 K
Slightly volatile
Other Non Cash Items1.9 M1.8 M540.3 K
Slightly volatile
Capital Expenditures18.6 K19.6 K191.4 K
Slightly volatile
Total Cash From Financing Activities19.8 M18.9 M6 M
Slightly volatile
End Period Cash Flow5.6 M6.7 M2.9 M
Slightly volatile
Change To Netincome764.7 K1.2 M501.8 K
Slightly volatile
Change To Inventory288.2 K324.2 K353.9 K
Slightly volatile
Dividends Paid24.5 M27.5 M30.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables952.7 K907.3 K355.4 K
Slightly volatile
Capex To Depreciation0.04440.04680.7944
Slightly volatile
Payables Turnover0.20.190.0744
Slightly volatile
Cash Per Share17.8318.77762
Slightly volatile
Days Payables Outstanding1.9 K2 K12.8 K
Slightly volatile
Income Quality0.590.720.6907
Pretty Stable
Current Ratio3.42.942.5036
Slightly volatile
Capex Per Share0.06680.070317.8425
Slightly volatile
Interest Debt Per Share0.20.211.4 K
Slightly volatile
Debt To Assets0.00570.0061.5484
Slightly volatile
Days Of Payables Outstanding1.9 K2 K12.8 K
Slightly volatile
Ebt Per Ebit1.541.231.2959
Pretty Stable
Quick Ratio3.42.942.5036
Slightly volatile
Cash Ratio3.042.412.3107
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.151.05
Pretty Stable
Debt Ratio0.00570.0061.5484
Slightly volatile

Transcode Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap25.7 M27.1 M3.7 B
Pretty Stable
Enterprise Value19.4 M20.4 M3.7 B
Pretty Stable

Transcode Fundamental Market Drivers

Transcode Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue22.9 K22.1 K
Cost Of Revenue615.1 K328 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY